Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV gp350 CAR-T cells
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBV gp350 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the Epstein-Barr virus (EBV) glycoprotein 350 (gp350). Gp350 is a major envelope glycoprotein of EBV and is highly expressed on the surface of cells during the viral lytic cycle and in certain EBV-associated malignancies. Developed by The First Affiliated Hospital of Zhengzhou University, this cell therapy involves engineering a patient's T cells to recognize and eliminate cells expressing gp350. It is primarily being evaluated for the treatment of relapsed or refractory EBV-positive lymphomas, where it aims to provide a targeted immunological response against the virus-driven tumor cells.
- Other names
- gp350-targeted CAR-T cellsgp-350-targeted CAR-T cellsgp 350-targeted CAR-T cellsEBV-targeted CAR-T cells
02
Targets
gp350 (Epstein-Barr virus glycoprotein 350)
Beyond the preview
Go deeper on EBV gp350 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV gp350 CAR-T cells.